Topic: rheumatoid arthritis

FDAApprovedStamp

The top 10 drug launches of 2017

Only 22 meds were greenlighted by the FDA in 2016, but no matter what tally the industry amasses this year, the crop will bring some would-be blockbusters and market disrupters.
Johnson & Johnson

J&J has a 'readiness plan' in place for Remicade biosim launch

Just yesterday, one of the biggest potential threats to Johnson & Johnson’s top line moved closer to reality as Pfizer announced it will begin shipping a biosimilar version of J&J’s blockbuster Remicade in late November. But executives of J&J, who had been insisting they wouldn’t face biosimilar competition this year, weren’t fazed during the company’s third-quarter earnings release.